Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031510 | 0.94 | DRD2 (0.47) | DRD2SIGMAR1TDP1SMN1; SMN2CACNA1H | |
| SCHEMBL5033974 | 0.89 | DRD2 (0.48) | DRD2SIGMAR1TDP1ALDH1A1CACNA1H | |
| SCHEMBL5856688 | 0.87 | DRD2 (0.59) | DRD2SIGMAR1TDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5031371 | 0.84 | DRD2 (0.48) | DRD2SIGMAR1TDP1CACNA1HMEN1 | |
| SCHEMBL30737220 | 0.83 | HTR4 (0.49) | DRD2SIGMAR1SMN1; SMN2 | |
| SCHEMBL24817867 | 0.83 | SIGMAR1 (0.47) | DRD2SIGMAR1TDP1CACNA1HMEN1 | |
| SCHEMBL5031377 | 0.83 | CACNA1H (0.47) | DRD2SIGMAR1TDP1CACNA1H | |
| SCHEMBL24817860 | 0.81 | MEN1 (0.46) | DRD2SIGMAR1TDP1ALDH1A1CACNA1H | |
| SCHEMBL30737121 | 0.81 | DRD2 (0.54) | DRD2SIGMAR1TDP1CACNA1HMEN1 | |
| SCHEMBL24619896 | 0.81 | DRD2 (0.54) | DRD2SIGMAR1TDP1CACNA1HMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670474-A4 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1670474-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005016879-A2 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, KCNH2, CACNA1B | DRD2 1459/4885SIGMAR1 1727/4885TDP1 4260/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | DRD2 2757/4885SIGMAR1 2043/4885TDP1 3629/4885 |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | HCN4, KCNH2, CACNA1B | DRD2 1459/4885SIGMAR1 1727/4885TDP1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.